

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

Apotex, Inc.,

Petitioner,

v.

UCB BIOPHARMA SPRL

Patent Owner.

Case IPR2019-00400

U.S. Patent No. 8,633,194

Title: Pharmaceutical composition of piperazine derivatives

**PETITIONER'S UPDATED MANDATORY NOTICE INFORMATION
UNDER 37 C.F.R. § 42.8**

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

IPR2019-00400

Patent 8,633,194 B2

Pursuant to 37 C.F.R. § 42.8(a)(3), Petitioner, Apotex, Inc. (“Apotex”), hereby submits the following updated mandatory notices:

B. Notice of Related Matters (37 C.F.R. § 42.8(b)(2))

1. Judicial Matters Involving the ’194 Patent

The ’194 patent is currently the subject of the following litigation: *UCB, Inc. et al. v. Apotex Inc.*, No. 0-18-cv-60846 (S.D. Fla.). On April 1, 2019, Judge Cooke of the Southern District of Florida issued an Order staying that case pending the PTAB’s *Inter Partes Review* of the ’194 patent.

Dated: April 2, 2019

Respectfully submitted,

/s/ Jitendra Malik

Jitendra Malik, Ph.D.

Alissa M. Pacchioli

Joseph M. Janusz

Katten Muchin Rosenman LLP

550 S. Tryon Street, Suite 2900

Charlotte, NC 28202-4213

jitty.malik@kattenlaw.com

alissa.pacchioli@kattenlaw.com

joe.janusz@kattenlaw.com

Lance Soderstrom

Katten Muchin Rosenman LLP

575 Madison Avenue

New York, NY 10022-2585

lance.soderstrom@kattenlaw.com

Counsel for Apotex, Inc.

IPR2019-00400
Patent 8,633,194 B2

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6 and 42.105, I hereby certify that on this 2nd day of April, 2019, the foregoing Petitioner's Updated Mandatory Notice Information Under 37 C.F.R. § 42.8 was served by filing this document through the Patent Trial and Appeal Board End to End System, as well as delivering a copy via electronic mail upon the following attorneys of record for the Petitioner:

James S. Trainor
Robert E. Counihan
Fenwick & West LLP
902 Broadway, Suite 14
New York, NY 10010
jtrainor@fenwick.com
rcounihan@fenwick.com

Erica R. Sutter
Fenwick & West LLP
801 California St.
Mountain View, CA 94041
esutter@fenwick.com

Date: April 2, 2019

Respectfully submitted,

/s/ Jitendra Malik (Electronically signed)
Jitendra Malik (Reg. No. 55,823)

Counsel for Apotex, Inc.